Xiao-Xiao Dinglin

750 total citations
15 papers, 425 citations indexed

About

Xiao-Xiao Dinglin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Xiao-Xiao Dinglin has authored 15 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Xiao-Xiao Dinglin's work include Lung Cancer Treatments and Mutations (6 papers), Cancer-related molecular mechanisms research (5 papers) and Lung Cancer Research Studies (5 papers). Xiao-Xiao Dinglin is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer-related molecular mechanisms research (5 papers) and Lung Cancer Research Studies (5 papers). Xiao-Xiao Dinglin collaborates with scholars based in China. Xiao-Xiao Dinglin's co-authors include Herui Yao, Hai Hu, Qian Hu, Qingjian Li, Xiaorong Lin, Xiaoding Xu, Xue Hou, Yuanyuan Zhao, Xing Yang and Xiao Lin and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Xiao-Xiao Dinglin

14 papers receiving 423 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiao-Xiao Dinglin China 8 271 215 124 118 28 15 425
Huohui Ou China 10 280 1.0× 212 1.0× 97 0.8× 81 0.7× 32 1.1× 16 405
Xiaoying Li China 9 250 0.9× 217 1.0× 88 0.7× 111 0.9× 37 1.3× 30 379
Fangzhou Ye China 9 174 0.6× 133 0.6× 102 0.8× 77 0.7× 49 1.8× 23 341
Yunhong Tian China 13 288 1.1× 197 0.9× 74 0.6× 68 0.6× 28 1.0× 21 420
Kunming Wen China 13 287 1.1× 151 0.7× 70 0.6× 136 1.2× 13 0.5× 29 417
Ram C. Shankaraiah Italy 10 188 0.7× 147 0.7× 56 0.5× 95 0.8× 42 1.5× 11 339
Xiangli Jiang China 14 307 1.1× 222 1.0× 171 1.4× 171 1.4× 15 0.5× 23 512
Piyada Sitthideatphaiboon Thailand 8 232 0.9× 128 0.6× 116 0.9× 129 1.1× 16 0.6× 24 379
Xiaoding Hu United States 13 284 1.0× 109 0.5× 91 0.7× 132 1.1× 19 0.7× 23 402
Ana Lameirinhas Portugal 12 269 1.0× 188 0.9× 54 0.4× 72 0.6× 19 0.7× 18 386

Countries citing papers authored by Xiao-Xiao Dinglin

Since Specialization
Citations

This map shows the geographic impact of Xiao-Xiao Dinglin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao-Xiao Dinglin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao-Xiao Dinglin more than expected).

Fields of papers citing papers by Xiao-Xiao Dinglin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiao-Xiao Dinglin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao-Xiao Dinglin. The network helps show where Xiao-Xiao Dinglin may publish in the future.

Co-authorship network of co-authors of Xiao-Xiao Dinglin

This figure shows the co-authorship network connecting the top 25 collaborators of Xiao-Xiao Dinglin. A scholar is included among the top collaborators of Xiao-Xiao Dinglin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiao-Xiao Dinglin. Xiao-Xiao Dinglin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Zhu, Di, Fei Ma, Yiqun Li, et al.. (2025). Abstract PS8-01: ZN-1041, a potential best-in-class BBB Penetrable HER2 Inhibitor, has high antitumor activity in patients with Breast Cancer with CNS Metastases. Clinical Cancer Research. 31(12_Supplement). PS8–1. 1 indexed citations
2.
Dinglin, Xiao-Xiao, Yongsheng Li, Qing Wen, et al.. (2025). BAT8008, a TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1 study.. Journal of Clinical Oncology. 43(16_suppl). 3024–3024.
3.
Ma, Fei, Yiqun Li, Herui Yao, et al.. (2023). Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.. Journal of Clinical Oncology. 41(16_suppl). 1040–1040. 4 indexed citations
4.
Lai, Hongna, Wei Jiang, Jianli Zhao, et al.. (2021). Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis. Journal of Cancer. 12(12). 3539–3547. 5 indexed citations
5.
Chen, Xinru, Xue Hou, Xiao-Xiao Dinglin, et al.. (2020). Treatment Patterns and Survival Outcomes of Non-Small Cell Lung Cancer Patients Initially Diagnosed With Brain Metastases in Real-World Clinical Practice. Frontiers in Oncology. 10. 581729–581729. 7 indexed citations
6.
Lin, Xiaorong, Xiao-Xiao Dinglin, Wen‐Ying Chen, et al.. (2020). Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR Cascade. Cell Reports. 31(10). 107753–107753. 64 indexed citations
7.
Hou, Xue, Delan Li, Ke Sai, et al.. (2020). Management of Non–Small-Cell Lung Cancer Patients Initially Diagnosed With 1 to 3 Synchronous Brain-Only Metastases: A Retrospective Study. Clinical Lung Cancer. 22(1). e25–e34. 11 indexed citations
8.
Bi, Zhuofei, Qingjian Li, Xiao-Xiao Dinglin, et al.. (2020). Nanoparticles (NPs)‐Meditated LncRNA AFAP1‐AS1 Silencing to Block Wnt/β‐Catenin Signaling Pathway for Synergistic Reversal of Radioresistance and Effective Cancer Radiotherapy. Advanced Science. 7(18). 2000915–2000915. 73 indexed citations
9.
Yang, Xing, Qian Hu, Xiaorong Lin, et al.. (2017). miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.. PubMed. 24(131). 75–85. 55 indexed citations
10.
Dinglin, Xiao-Xiao, Lin Ding, Qingjian Li, et al.. (2017). RYBP Inhibits Progression and Metastasis of Lung Cancer by Suppressing EGFR Signaling and Epithelial-Mesenchymal Transition. Translational Oncology. 10(2). 280–287. 23 indexed citations
11.
Wu, Xiaoliang, Xiao-Xiao Dinglin, Xing Wang, et al.. (2017). Long noncoding RNA XIST promotes malignancies of esophageal squamous cell carcinoma via regulation of miR-101/EZH2. Oncotarget. 8(44). 76015–76028. 64 indexed citations
12.
Qin, Tao, Ningning Zhou, Xiao-Xiao Dinglin, et al.. (2016). Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase. OncoTargets and Therapy. 9. 1095–1095. 6 indexed citations
13.
Hu, Qian, Junxia Jiang, Xing Yang, et al.. (2015). Comparing single‐agent with doublet chemotherapy in first‐line treatment of advanced non‐small cell lung cancer with performance status 2: A meta‐analysis. Asia-Pacific Journal of Clinical Oncology. 11(3). 253–261. 4 indexed citations
14.
Liang, Wenhua, Xuan Wu, Wenfeng Fang, et al.. (2014). Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. PLoS ONE. 9(2). e85245–e85245. 105 indexed citations
15.
Hu, Qian, Junxia Jiang, Xing Yang, et al.. (2014). A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer. SpringerPlus. 3(1). 293–293. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Huohui Ou Breakdown of academic impact, for papers by Xiaoying Li Breakdown of academic impact, for papers by Fangzhou Ye Breakdown of academic impact, for papers by Yunhong Tian Breakdown of academic impact, for papers by Kunming Wen Breakdown of academic impact, for papers by Ram C. Shankaraiah Breakdown of academic impact, for papers by Xiangli Jiang Breakdown of academic impact, for papers by Piyada Sitthideatphaiboon Breakdown of academic impact, for papers by Xiaoding Hu Breakdown of academic impact, for papers by Ana Lameirinhas
Rankless by CCL
2026